All In Biotech

Drug Trial Radar · NCT06010303

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Nov 8, 2023

Primary completion

May 30, 2025

Study completion May 7, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Aug 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Conditions

  • Esophageal Cancer
  • Esophageal Squamous Cell Carcinoma
  • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

Interventions

  • LBL-007Drug

    LBL-007 will be administered at a standard dose intravenously.

  • TislelizumabDrug

    Tislelizumab will be administered at a standard dose intravenously.

  • Chemotherapy DoubletDrug

    Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Approximately 10 months

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Nantong Tumor Hospital Branch North

    Nantong, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • The Second Affiliated Hospital of Shandong First Medical University

    Taian, Shandong, China

  • Sichuan Cancer Hospital and Institute

    Chengdu, Sichuan, China

  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

  • Chonnam National University Hwasun Hospital

    HwasunGun, Jeollanam-do, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, Seoul Teugbyeolsi, South Korea

  • The Catholic University of Korea, Seoul St Marys Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Ramathibodi Hospital Mahidol University

    Bangkok, Thailand

  • Siriraj Hospital

    Bangkok, Thailand

  • Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University)

    Ongkharak, Thailand

  • Phramongkutklao Hospital

    Ratchathewi, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.